| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11019006 | Heart, Lung and Circulation | 2018 | 27 Pages |
Abstract
Glucagon like peptide-1 therapy was associated with a significant reduction in cardiovascular (CV) death. However, GLP-1 agonists seem to have a safety profile comparable to placebo in terms of reducing non-fatal myocardial infarction (MI), non-fatal stroke events, and rates of HF hospitalisation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Majed S. PharmD, BCPS, ASH-CHC, Osamah M. PharmD, CDE, Razan PharmD, BCPS,